Bio Essence CEO proposes sale of 550,000 shares

Glendale Securities is listed in connection with the proposed sale, which has an aggregate market value of $148,500.

Rhea-AI Filing Summary

Bio Essence Corp. lists a proposed sale by Yin Yan, its Director and Chief Executive Officer, of 550,000 common shares, with an aggregate market value of $148,500. The notice gives October 12, 2026 as the approximate sale date and lists Glendale Securities as the broker and OTC as the exchange.

Key Figures

Shares proposed for sale: 550,000 shares Aggregate market value: $148,500 Shares outstanding: 55,809,000 shares

3 metrics

Shares proposed for sale 550,000 shares Common stock; approximate sale date October 12, 2026

Aggregate market value $148,500 Proposed sale

Shares outstanding 55,809,000 shares Figure listed with the proposed-sale details

Key Terms

Rule 144, Founder Shares, OTC

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Founder Shares financial

"Founder Shares"

Founder shares are the ownership stakes given to the people who start a company, often with extra voting power or protections compared with ordinary shares. For investors, they matter because founders’ control and incentives influence decisions about strategy, hiring, and whether the company sells or stays independent — like a family that keeps majority voting rights in a household decision. High founder ownership can mean stable leadership but also a risk that outside shareholders have less influence.

OTC financial

"OTC"

OTC stands for "over-the-counter" and describes securities that trade directly between dealers or via dealer networks rather than on a formal stock exchange. It matters to investors because OTC listings typically have fewer reporting rules and lower trading volume, which can mean higher price swings, limited liquidity, and greater difficulty buying or selling shares—similar to shopping at a small flea market instead of a large, regulated supermarket.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BIOE shares does Yin Yan plan to sell?

Yin Yan's notice lists a proposed sale of 550,000 common shares, with an aggregate market value of $148,500 and an approximate sale date of October 12, 2026.

Which broker is listed for Yin Yan's BIOE sale?

Glendale Securities is listed as the broker for the proposed sale. The corresponding exchange field reads OTC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 06:18 AM EDT Accepted by SEC EDGAR 10/13/2026 - 06:17 AM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001990397
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIO ESSENCE CORP.
SEC File Number	000-56263
Address of Issuer	2955 Main Street, Suite 202 Irvine CALIFORNIA 92618
Phone	949-706-9966
Name of Person for Whose Account the Securities are To Be Sold	YIN YAN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director and Chief Executive Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Glendale Securities 15233 Ventura Blvd. Ste 712 Sherman Oaks CA 91403	550000	148500.00	55809000	10/12/2026	OTC QB

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	12/08/2017	Founder Shares	Bio Essence Corp.			9000000	12/08/2017	Capital Investment

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Yin Yan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)